Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2015.

In this Issue:

› EU marketing approval granted for VivaGel^® BV
› Multi-product DEP^® license with AstraZeneca
› VivaGel^® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel^® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Starpharma today announced the granting of a patent by the US Patent Office for VivaGel^® related to the prevention of recurrence of bacterial vaginosis (BV). The patent’s term is to 2032 providing an extension of seven years over granted VivaGel^® patents. Additional term may also be available subject to timing of regulatory approval.

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX  investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.